PriceTargets.com logo

Capstone Therapeutics - CAPS Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.86 As of 12/4/2025 05:00 PM ET
▲ +0.0278 (3.34%)

This chart shows the closing price for CAPS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Capstone Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CAPS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CAPS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Capstone Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.86.

This chart shows the closing price for CAPS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 investment analysts is to sell stock in Capstone Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/17/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
11/5/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/14/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Capstone Therapeutics logo
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Read More

Today's Range

Now: $0.86
Low: $0.80
High: $0.86

50 Day Range

MA: $1.05
Low: $0.75
High: $1.40

52 Week Range

Now: $0.86
Low: $0.73
High: $16.18

Volume

115,249 shs

Average Volume

531,867 shs

Market Capitalization

$7.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Capstone Therapeutics?

The following Wall Street analysts have issued reports on Capstone Therapeutics in the last year: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for CAPS.

What is the current price target for Capstone Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Capstone Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Capstone Therapeutics in the next year.
View the latest price targets for CAPS.

What is the current consensus analyst rating for Capstone Therapeutics?

Capstone Therapeutics currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe CAPS will underperform the market and that investors should sell shares of Capstone Therapeutics.
View the latest ratings for CAPS.

What other companies compete with Capstone Therapeutics?

Other companies that are similar to Capstone Therapeutics include SCYNEXIS, Liminatus Pharma, Passage Bio, iBio and Lunai Bioworks. Learn More about companies similar to Capstone Therapeutics.

How do I contact Capstone Therapeutics' investor relations team?

Capstone Therapeutics' physical mailing address is 5141 W. 122ND STREET, ALSIP, IL, 60803. The company's listed phone number is (708) 371-0660 and its investor relations email address is [email protected]. The official website for Capstone Therapeutics is www.capstonethx.com. Learn More about contacing Capstone Therapeutics investor relations.